Loading...
XSHG600566
Market cap3.78bUSD
Dec 24, Last price  
30.09CNY
1D
2.24%
1Q
15.95%
Jan 2017
-3.74%
Name

Hubei Jumpcan Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600566 chart
P/E
9.77
P/S
2.86
EPS
3.08
Div Yield, %
2.94%
Shrs. gr., 5y
2.37%
Rev. gr., 5y
6.02%
Revenues
9.65b
+7.32%
146,141,239176,159,758200,716,165218,550,423212,985,977222,018,131237,141,110240,469,821160,020,6712,447,577,6112,986,412,1543,767,836,3744,677,891,5615,642,009,1387,208,205,7886,939,993,8116,164,974,1677,630,510,0008,996,366,9799,654,537,192
Net income
2.82b
+30.04%
7,427,6048,431,8598,935,54210,875,6988,379,4787,708,5208,462,6997,916,4820402,723,954519,392,597686,571,187934,182,9421,223,463,5111,687,863,2601,622,973,8931,277,212,4861,719,175,9312,170,749,9232,822,781,164
CFO
3.46b
+32.17%
063,378,2844,242,18536,720,00123,053,3624,917,24851,128,274411,23727,010,322287,164,897616,112,024645,475,175913,095,3891,188,750,4191,709,147,3192,147,676,1121,781,691,1631,894,329,3922,620,832,8793,463,958,632
Dividend
Jun 17, 20241.3 CNY/sh

Profile

Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. The company offers Chinese and western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatrics; oral and skin care products; and anti-fatigue, anti-aging, antioxidant, and immunity-enhancing Chinese medicine health products. It also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis. The company was formerly known as Hubei Hongcheng General Machinery Co., Ltd and changed its name to Hubei Jumpcan Pharmaceutical Co., Ltd. in March 2015. Hubei Jumpcan Pharmaceutical Co., Ltd. is based in Taixing, China.
URL
https://www.jumpcan.com/
IPO date
Aug 22, 2001
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
9,654,537
7.32%
8,996,367
17.90%
7,630,510
23.77%
Cost of revenue
6,154,434
6,293,602
5,600,776
Unusual Expense (Income)
NOPBT
3,500,103
2,702,765
2,029,734
NOPBT Margin
36.25%
30.04%
26.60%
Operating Taxes
470,027
336,197
233,219
Tax Rate
13.43%
12.44%
11.49%
NOPAT
3,030,077
2,366,568
1,796,515
Net income
2,822,781
30.04%
2,170,750
26.27%
1,719,176
34.60%
Dividends
(811,111)
(604,030)
(399,716)
Dividend yield
2.82%
2.44%
1.57%
Proceeds from repurchase of equity
(35,665)
BB yield
0.12%
Debt
Debt current
1,043,077
400,444
629,101
Long-term debt
2,869
404
2,033
Deferred revenue
71,433
78,192
84,634
Other long-term liabilities
820
1,060
1,353
Net debt
(10,264,278)
(7,462,644)
(4,862,862)
Cash flow
Cash from operating activities
3,463,959
2,620,833
1,894,329
CAPEX
(301,645)
Cash from investing activities
(476,350)
Cash from financing activities
(150,689)
(117,582)
FCF
3,194,219
2,715,425
1,838,878
Balance
Cash
10,916,253
7,863,492
5,493,996
Long term investments
393,972
Excess cash
10,827,498
7,413,674
5,112,471
Stockholders' equity
9,319,933
7,304,102
5,872,842
Invested Capital
5,165,695
4,230,583
4,607,633
ROIC
64.50%
53.55%
39.88%
ROCE
23.98%
23.19%
20.64%
EV
Common stock shares outstanding
916,487
908,266
899,066
Price
31.43
15.47%
27.22
-3.95%
28.34
40.09%
Market cap
28,805,199
16.51%
24,722,988
-2.97%
25,479,537
50.88%
EV
18,560,342
17,332,165
20,630,845
EBITDA
3,804,210
3,011,566
2,323,540
EV/EBITDA
4.88
5.76
8.88
Interest
17,584
30,409
34,899
Interest/NOPBT
0.50%
1.13%
1.72%